GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.